Video Experimental Relacionado
Updated: Aug 10, 2026
06:29
Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
Published on: May 5, 2023
La inhibición de la maduración pulmonar por anticuerpos monoclonales contra el factor de los
Nature
|March 15, 1984
Resumen
El factor de los fibroblastos-pneumonocitos juega un papel clave en la maduración del pulmón fetal al estimular la producción de tensioactivos. El bloqueo de este factor retrasa el desarrollo pulmonar, lo que confirma su importancia fisiológica.
Área de la Ciencia:
- La bioquímica es la bioquímica.
- Biología del desarrollo Biología del desarrollo.
- Biología celular Biología celular.
Sus antecedentes:
- La maduración pulmonar fetal es crucial para la función respiratoria después del nacimiento.
- Los glucocorticoides regulan la síntesis de surfactantes, pero su mecanismo es indirecto.
- El mesénquima pulmonar produce el factor fibroblasto-pneumonocitario (FPF) en respuesta a los glucocorticoides, estimulando las células de tipo II.
Objetivo del estudio:
- Para generar anticuerpos monoclonales contra el factor pulmonar de fibroblastos-neumonocitos (FPF) en ratas.
- Investigar el papel de la FPF en la maduración pulmonar fetal utilizando estos anticuerpos.
- Confirmar la FPF como mediador fisiológico en el desarrollo pulmonar prenatal.
Principales métodos:
- Generación de hibridomas que producen anticuerpos monoclonales contra el FPF de rata.
- Prueba de los efectos de los anticuerpos en la síntesis de fosfatidilcolina estimulada por el cortisol en cultivos pulmonares de ratas fetales.
- Evaluación de la maduración pulmonar en pollitos embrionarios inyectados con anticuerpos.
Principales resultados:
- Dos anticuerpos monoclonales redujeron la síntesis de surfactante estimulada por cortisol in vitro.
- Estos anticuerpos bloquearon el efecto estimulante de la FPF en las células de tipo II.
- In vivo, la inyección de anticuerpos retrasó la maduración pulmonar en pollitos embrionarios, lo que demuestra la especificidad del órgano.
Conclusiones:
- FPF es un mediador crítico en la maduración pulmonar fetal inducida por glucocorticoides.
- Los anticuerpos monoclonales contra la FPF pueden inhibir el desarrollo prenatal del pulmón.
- Estos hallazgos apoyan un papel fisiológico significativo de la FPF en el desarrollo pulmonar.
Videos de Conceptos Relacionados
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:23Cystic Fibrosis: Pathogenesis
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.